H. Wieland

发表

Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K/Akt/FOXO and AMPK Pathways

Lanyang Gao, Danli Zhu, Qin Wang, 2021, Frontiers in Oncology.

Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.

W. März, H. Scharnagl, H. Wieland, 2001, Biochemical pharmacology.

Low-density lipoprotein particle diameter and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.

W. März, W. Koenig, M. Kleber, 2015, European heart journal.

Coronary artery disease Low-density lipoprotein particle diameter and mortality : the Ludwigshafen Risk and Cardiovascular Health Study

W. März, W. Koenig, M. Kleber, 2015 .

Molecular basis of type III hyperlipoproteinemia in Germany

W. März, H. Wieland, M. Hoffmann, 1998, Human mutation.

Apolipoprotein E5 (Glu212-->Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts.

W. März, H. Scharnagl, H. Wieland, 1996, Journal of lipid research.

Elimination of Liposomes by Different Separation Principles Used in Low‐density Lipoprotein Apheresis

H. Wieland, O. Schmah, K. Winkler, 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment

W. März, G. Assmann, H. Wieland, 1997 .

Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment.

A. von Eckardstein, W. März, G. Assmann, 1997, Clinical chemistry.

Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated.

W. März, H. Wieland, M. Nauck, 1996, Clinical chemistry.

Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes.

W. März, H. Wieland, M. Nauck, 2000, Clinical chemistry.

Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6.

H. Wieland, M. Nauck, M. Bihl, 1998, American journal of respiratory cell and molecular biology.

The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs.

W. März, B. Winkelmann, H. Wieland, 2001, Pharmacogenomics.

Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease.

W. März, B. Winkelmann, D. Galton, 1999, American heart journal.

Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

W. März, B. Boehm, B. Winkelmann, 2007, Clinical chemistry.

Lipid metabolic changes during hormonal treatment of endometriosis.

H. Wieland, P. Cremer, D. Seidel, 1988, Maturitas.

Effects of medrogestone and conjugated oestrogens on serum lipid and lipoprotein concentrations.

H. Wieland, P. Cremer, D. Seidel, 1985, Maturitas.

Significance and Need of Screening for Hyperlipidemia in Childhood

H. Wieland, D. Seidel, 1980 .

Improved techniques for assessment of plasma lipoprotein patterns. I. Precipitation in gels after electrophoresis with polyanionic compounds.

H. Wieland, D. Seidel, C. Ruppert, 1973, Clinical chemistry.

The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations

W. März, H. Scharnagl, H. Wieland, 2001, Clinical chemistry and laboratory medicine.

The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

V. Armstrong, H. Wieland, P. Cremer, 1986, Atherosclerosis.

A simple specific method for precipitation of low density lipoproteins.

H. Wieland, D. Seidel, 1983, Journal of lipid research.

Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia.

W. März, M. Baumstark, H. Wieland, 2003, The Journal of clinical endocrinology and metabolism.

Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype

W. März, H. Scharnagl, J. Keul, 2001, Circulation.

Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation.

W. März, M. Baumstark, H. Wieland, 2000, The Journal of clinical endocrinology and metabolism.

Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis.

W. März, H. Wieland, M. Nauck, 1995, Journal of Lipid Research.

Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves.

W. März, H. Wieland, M. Nauck, 1999, Clinical chemistry.

Chromatofocusing of human high density lipoproteins and isolation of lipoproteins A and A-I.

H. Wieland, D. Seidel, A. C. Nestruck, 1983, Biochimica et biophysica acta.

Quantification of plasma lipoprotein cholesterol: a simple procedure for enzymatic determination of cholesterol in electrophoretically separated lipoproteins.

H. Wieland, D. Seidel, M. Bartholomé, 1980, Clinica chimica acta; international journal of clinical chemistry.

Serum lipoproteins and coronary artery disease (CAD) Comparison of the lipoprotein profile with the results of coronary angiography

H. Wieland, V. Wiegand, H. Kreuzer, 1980 .

Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients?

W. März, C. Wanner, H. Wieland, 1996, Clinical nephrology.

A New Liquid Homogeneous Assay for HDL Cholesterol Determination Evaluated in Seven Laboratories in Europe and the United States

W. März, M. König, N. Rifai, 1999, Clinical chemistry and laboratory medicine.

A New Liquid Homogeneous Assay for the Determination of HDL-Cholesterol

W. März, H. Wieland, M. Nauck, 1999, Clinical chemistry and laboratory medicine.

New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol.

W. März, H. Wieland, M. Nauck, 1998, Clinical chemistry.

Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis.

C. Wanner, W. Hörl, H. Wieland, 1991, Kidney international.

Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability.

H. Wieland, M. Orth, C. Luley, 1995, Thrombosis research.

Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements.

W. März, H. Scharnagl, H. Wieland, 2000, Arteriosclerosis, thrombosis, and vascular biology.

W. März, B. Boehm, B. Winkelmann, 2007, Clinical Chemistry.

Rapid Detection of Missense Mutations in the Prostatic Steroid 5α-Reductase Gene Using Real-Time Fluorescence PCR and Melting Curve Analysis

W. März, H. Wieland, M. Nauck, 2002 .

Six Methods for the Determination of C-Peptide Evaluated

W. März, M. Nauck, H. Wieland, 1999, Clinical Chemistry and Laboratory Medicine.

Evaluation of immunoaffinity chromatography for isolating human lipoproteins containing apolipoprotein B.

H. Wieland, H. Kloer, P. Alaupovic, 1985, Journal of chromatography.

Reference values for serum silicon in adults.

H. Wieland, E. Bissé, G. Lindinger, 2005, Analytical biochemistry.

Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia.

W. März, C. Pullinger, H. Wieland, 1998, Clinical chemistry.

Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 (Arg3500-->Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405-->Gln) diminishes receptor-mediated uptake of LDL.

W. März, H. Scharnagl, E. Fisher, 1999, Clinical chemistry.

Lifibrol: first member of a new class of lipid-lowering drugs?

W. März, H. Scharnagl, H. Wieland, 1997, Expert opinion on investigational drugs.

Results from a European multicentre evaluation of immunoturbidimetric assays for apolipoproteins AI and B

H. Wieland, F. Huchet, J. Patsch, 1991 .

A New, Sensitive Method for Measuring Low-Density Lipoproteins and Its Application to the Screening for Hyperlipoproteinemia

V. Armstrong, H. Wieland, D. Seidel, 1984 .

Influence of Training Volume and Acute Physical Exercise on the Homocysteine Levels in Endurance-Trained Men: Interactions with Plasma Folate and Vitamin B12

H. Wieland, D. König, E. Bissé, 2003, Annals of Nutrition and Metabolism.

Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol.

W. März, H. Wieland, M. Nauck, 1995, Clinical chemistry.

Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells.

C. Wanner, H. Pavenstädt, H. Wieland, 1994, Journal of the American Society of Nephrology : JASN.

Receptor-mediated uptake of IDL and LDL from nephrotic patients by glomerular epithelial cells.

C. Wanner, H. Pavenstädt, H. Wieland, 1993, Kidney international.

Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high-density lipoprotein-deficient, and apolipoprotein E-deficient plasmas.

A. von Eckardstein, W. März, G. Assmann, 2000, Metabolism: clinical and experimental.

Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins.

H. Wieland, M. Orth, W. Gerok, 1989, European journal of biochemistry.

Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype.

H. Wieland, M. Orth, C. Luley, 1996, Biochimica et biophysica acta.

The molecular mechanisms of inherited hypercholesterolemia

W. März, E. Fisher, H. Wieland, 2000 .

FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia.

W. März, H. Scharnagl, M. Nauck, 2000, Atherosclerosis.

Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol.

W. März, W. Koenig, H. Scharnagl, 2004, The American journal of cardiology.

Hypertriglyceridaemia Secondary to Liver Disease

H. Wieland, D. Seidel, B. Agostini, 1974, European journal of clinical investigation.

Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation.

W. März, M. Baumstark, H. Wieland, 2000, The Journal of clinical endocrinology and metabolism.

Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome

D. Rader, C. Wanner, H. Brewer, 1993, Annals of Internal Medicine.

Hypertriglyceridaemia Secondary to Liver Disease

H. Wieland, D. Seidel, B. Agostini, 1974 .

Evaluation of the Roche Diagnostics LightCycler-Apo B 3500 Mutation Detection Kit

W. März, H. Wieland, M. Nauck, 2000, Clinical chemistry and laboratory medicine.

Low-density lipoprotein susceptibility to in vitro oxidation in healthy smokers and nonsmokers.

W. März, H. Wieland, W. Gross, 1996, Clinical chemistry.

Lipoprotein-Associated Phospholipase A 2 Predicts 5-Year Cardiac Mortality Independently of Established Risk Factors and Adds Prognostic Information in Patients with Low and Medium High-Sensitivity C-Reactive Protein (The Ludwigshafen Risk and Cardiovascular Health Study)

W. März, B. Boehm, B. Winkelmann, 2007 .

Rapid genotyping of human platelet antigen 1 (HPA‐1) with fluorophore‐labelled hybridization probes on the LightCyclerTM

W. März, M. Nauck, H. Wieland, 1999 .

Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 μg or 30 μg) and levonorgestrel (100 μg or 150 μg) on lipoprotein metabolism

W. März, H. Scharnagl, M. Nauck, 2004 .

Original research article Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 go r 30 g) and levonorgestrel (100 go r 150g) on lipoprotein metabolism

H. Scharnagl, M. Nauck, H. Wieland, 2004 .

C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

W. März, B. Winkelmann, H. Wieland, 2002, The American journal of cardiology.

Influence of smoking on the plasma lipoprotein profile.

H. Wieland, P. Cremer, D. Seidel, 1984, Klinische Wochenschrift.

Cord Blood Levels of Interleukin-6 and Interleukin-8 for the Immediate Diagnosis of Early-Onset Infection in Premature Infants

M. Krueger, R. Hentschel, H. Wieland, 2001, Neonatology.

Assessment of vitamin B-12, folate, and vitamin B-6 status and relation to sulfur amino acid metabolism in neonates.

H. Wieland, J. Lütschg, E. Bissé, 2000, The American journal of clinical nutrition.

Pre-analytical Conditions Affecting the Determination of the Plasma Homocysteine Concentration

H. Wieland, M. Nauck, E. Bissé, 2001, Clinical chemistry and laboratory medicine.

Beclobrate: pharmacodynamic properties and therapeutic use in hyperlipidemia

C. Wanner, W. Hörl, H. Wieland, 2011, European Journal of Clinical Pharmacology.

Beclobrate: Pharmacodynamic properties and therapeutic use in hyperlipidemia

C. Wanner, W. Hörl, H. Wieland, 2005, European Journal of Clinical Pharmacology.

High-performance liquid chromatographic separation of human haemoglobins. Simultaneous quantitation of foetal and glycated haemoglobins.

H. Wieland, E. Bissé, 1988, Journal of chromatography.

Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.

W. März, H. Scharnagl, M. Baumstark, 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism.

W. März, H. Scharnagl, M. Nauck, 2004, Contraception.

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

W. März, M. Baumstark, H. Wieland, 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Chromatographic evaluation of minor hemoglobins: clinical significance of hemoglobin A1d, comparison with hemoglobin A1c, and possible interferences.

H. Wieland, E. Bissé, P. Huaman-Guillen, 1995, Clinical chemistry.

Endocrine and metabolic abnormalities following kidney transplantation

C. Wanner, W. Hörl, H. Wieland, 1989, Klinische Wochenschrift.

Is lipoprotein(a) cholesterol a significant indicator of cardiovascular risk?

W. März, H. Wieland, M. Nauck, 2000, Clinical chemistry.

USP7 regulates melanoma progression through PI3K/Akt/FOXO and AMPK Pathways

Lanyang Gao, Qin Wang, Zheng Bao, 2020 .

Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.

W. März, H. Scharnagl, H. Wieland, 1999, Journal of lipid research.

Enzymic Determinationof Branched-ChainAmino Acids

G. Michal, H. Wieland, D. Gerbitz, 1981 .

Low-densitylipoprotein susceptibility to in vitro oxidation in healthysmokersand nonsmokers

H. Wieland, Rudiger Siekmeler, P. Wulfroth, 1996 .

The role of the liver in postprandial hypertriglyceridaemia

H. Wieland, M. Orth, C. Luley, 1993 .

Biosynthesis and excretion of gangliosides by the isolated perfused rat liver.

D. Häussinger, H. Wieland, W. Gerok, 1992, European journal of biochemistry.

Altered concentrations, patterns and distribution in lipoproteins of serum gangliosides in liver diseases of different etiologies.

J. Schölmerich, H. Wieland, M. Orth, 1990, Journal of hepatology.

An optimized method for measuring lecithin : cholesterol acyltransferase activity, independent of the concentration and quality of the physiological substrate.

H. Wieland, D. Seidel, D. Niedmann, 1981, Biochimica et biophysica acta.

Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes.

W. März, H. Wieland, H. Gierens, 2001, Clinical biochemistry.

Determination of apolipoprotein B by kinetic (rate) nephelometry.

H. Wieland, P. Cremer, D. Seidel, 1982, Journal of lipid research.

Responsiveness of atiii and coagulation factors V and VII to a standardized oral fat load.

H. Wieland, M. Orth, C. Luley, 1995, Thrombosis research.

Haemoglobin Hokusetsu [β52 (D3)] Asp→Gly in German families associated with inclusion body

H. Wieland, C. Schaeffer, A. Dorsselaer, 2008, Annals of Hematology.

Fluorometric determination of total retinyl esters in triglyceride-rich lipoproteins.

H. Wieland, M. Orth, M. Porsch-Ozcürümez, 1998, Clinical chemistry.

Improved assessment of plasma lipoprotein patterns. III. Direct measurement of lipoproteins after gel-electrophoresis.

H. Wieland, G. Baggio, D. Seidel, 1977, Clinical chemistry.

Improved assessment of plasma lipoprotein patterns. IV. Simple preparation of a lyophilized control serum containing intact human plasma lipoproteins.

H. Wieland, D. Seidel, 1982, Clinical chemistry.

D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients.

W. März, H. Wieland, I. Walter‐Sack, 1998, Journal of the American Society of Nephrology : JASN.

Further Aspects on the Characterization of High and Very Low Density Lipoproteins in Patients with Liver Disease

H. Wieland, H. Greten, D. Seidel, 1972, European journal of clinical investigation.

Hair iron content: possible marker to complement monitoring therapy of iron deficiency in patients with chronic inflammatory bowel diseases?

J. Schölmerich, H. Wieland, E. Bissé, 1996, Clinical chemistry.

Medroxyprogesterone acetate and lipid metabolic changes.

H. Wieland, P. Cremer, D. Seidel, 1987, Arzneimittel-Forschung.

Hemoglobin Rambam (beta69[E13]Gly-->Asp), a pitfall in the assessment of diabetic control: characterization by electrospray mass spectrometry and HPLC.

W. März, A. van Dorsselaer, H. Wieland, 1998, Clinical chemistry.

Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL.

H. Wieland, M. Orth, W. Gerok, 1992, Atherosclerosis.

Isolation and characterization of lipoprotein‐X (LP‐X) from canine

H. Wieland, R. Fellin, D. Seidel, 1973, FEBS letters.

Glycosylation of serum albumin: Elevated glycosyl‐albumin in diabetic patients

H. Wieland, R. Dolhofer, 1979, FEBS letters.

Heterozygosity for the IVS-I-5 (G-->C) mutation with a G-->A change at codon 18 (Val-->Met; Hb Baden) in cis and a T-->G mutation at codon 126 (Val-->Gly; Hb Dhonburi) in trans resulting in a thalassemia intermedia.

H. Wieland, T. Huisman, E. Bissé, 1992, Biochimica et biophysica acta.

Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids.

H. Wieland, O. Eickelberg, M. Nauck, 1997, American journal of respiratory cell and molecular biology.

[Experimental studies of the effect of single and fractionated x-irradiation on subcutaneous Walker carcinoma in rats under respiration with various increased oxygen partial pressures].

H. Wieland, G. Grussner, 1956, Strahlentherapie.

The interleukin-6 G(–174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction

W. März, B. Winkelmann, H. Wieland, 2002, Journal of Molecular Medicine.

The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).

H. Wieland, L. Kappenberger, P. Betz, 1997, European heart journal.

Selective continuous extracorporal elimination of low-density lipoproteins with heparin at acidic pH.

V. Armstrong, H. Wieland, D. Seidel, 1983, Transactions - American Society for Artificial Internal Organs.

Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome

C. Wanner, H. Wieland, P. Schollmeyer, 1995, Pediatric Nephrology.

Assessment of Lipoproteins

H. Wieland, 1997 .

Selective removal of low density lipoproteins (LDL) by precipitation at low pH: First clinical application of the HELP system

V. Armstrong, H. Wieland, T. Eisenhauer, 1987, Klinische Wochenschrift.

Selective Continuous Extracorporeal Elimination of Low-Density Lipoproteins from Plasma by Heparin Precipitation without Cations

V. Armstrong, H. Wieland, D. Seidel, 1983 .

Effects of Lovastatin and Pravastatin on the Survival of Hamsters With Inherited Cardiomyopathy

W. März, H. Wieland, H. Müller, 2000, Journal of cardiovascular pharmacology and therapeutics.

Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labelled hybridization probes on the LightCycler.

W. März, H. Wieland, H. Gierens, 1999, British journal of haematology.

HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia.

W. März, H. Scharnagl, H. Wieland, 2000, Atherosclerosis.

The βA4 Amyloid Peptide Enhances Cellular Uptake of Apolipoprotein E-Containing Lipoproteins by the Low-Density Lipoprotein Receptor-Related Protein/α2-Macroglobulin Receptor

W. März, H. Scharnagl, T. Ohm, 1996 .

HMG-CoA Reductase Inhibition: Anti-Inflammatory Effects beyond Lipid Lowering?

W. März, H. Wieland, 2000, Herz.

Die Differentialdiagnostik von Fettstoffwechselstörungen unter besonderer Berücksichtigung methodischer Aspekte. Differential Diagnostics of Disorders in Lipid Metabolism with Special Consideration of Methodical Aspects

H. Wieland, M. Nauck, 2001 .

Diagnostics of Lipids and Lipoproteins

W. März, H. Wieland, M. Nauck, 1994 .

A free fatty acid tolerance test identifies patients with coronary artery disease among individuals with a low conventional coronary risk profile

H. Wieland, C. Luley, S. Westphal, 2002, Heart and Vessels.

Evaluation of the apo E genotyping kit on the LightCycler.

W. März, H. Wieland, M. Nauck, 2000, Clinical chemistry.

Simple precipitation-based method for the screening of type III hyperlipoproteinemia.

W. März, H. Wieland, M. Nauck, 1999, Clinical chemistry.

Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.

W. März, H. Scharnagl, E. Fisher, 1998, Journal of lipid research.

Apolipoprotein E 2 ( Arg 136 → Cys ) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia 1

W. März, H. Scharnagl, E. Fisher, 1998 .

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

W. März, M. Baumstark, H. Wieland, 2003, Diabetes care.

Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28-->Pro), on lipoproteins and the prevalence of coronary artery disease in whites.

R. Mahley, G. Assmann, K. Weisgraber, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Rapid apolipoprotein E phenotyping by immunofixation in agarose.

M. Baumstark, H. Wieland, C. Luley, 1991, Journal of lipid research.

Adding albumin normalizes electrophoretic mobility of lipoproteins in sera with high concentrations of free fatty acids.

W. März, H. Wieland, M. Nauck, 1996, Clinical chemistry.

Improvement of apolipoprotein E phenotyping by isoelectric focusing/immunofixation.

H. Wieland, B. Haas, C. Luley, 1992, Clinical chemistry.

Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients.

C. Wanner, W. Hörl, H. Wieland, 1989, Kidney international. Supplement.

Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining.

M Nauck, W. März, H. Wieland, 1995, Clinical chemistry.

Influence of bile acids and free fatty acids on physicochemical properties of LP-X

H. Wieland, G. Baggio, D. Seidel, 1978, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

The molecular mechanisms of inherited thrombophilia

W. März, H. Wieland, M. Nauck, 2000, Zeitschrift für Kardiologie.

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.

W. März, H. Wieland, M. Hoffmann, 2004, The Journal of clinical endocrinology and metabolism.

The Diagnostic Value of Serum Homocysteine Concentration as a Risk Factor for Coronary Artery Disease

H. Wieland, C. Luley, M. Orth, 1998, Clinical chemistry and laboratory medicine.

Evaluation of the Roche diagnostics LightCycler-Factor V Leiden Mutation Detection Kit and the LightCycler-Prothrombin Mutation Detection Kit.

W. März, H. Wieland, M. Nauck, 2000, Clinical biochemistry.

Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.

W. März, H. Scharnagl, H. Wieland, 2001, Journal of the American Society of Nephrology : JASN.

Competition of Aβ amyloid peptide and apolipoprotein E for receptor-mediated endocytosis

W. März, H. Scharnagl, H. Wieland, 1999 .

Serum lipoproteins and coronary artery disease (CAD). Comparison of the lipoprotein profile with the results of coronary angiography.

H. Wieland, V. Wiegand, H. Kreuzer, 1980, Atherosclerosis.

Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia

W. März, H. Scharnagl, H. Wieland, 2001, Human mutation.

Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.

W. März, M. Baumstark, H. Wieland, 2002, The Journal of clinical endocrinology and metabolism.

The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway.

W. März, H. Scharnagl, H. Wieland, 2000, Atherosclerosis.

Electron microscopy of low-density plasmalipo-proteins in patients with type IIa hyperlipoproteinemia

H. Wieland, D. Seidel, B. Agostini, 1973, Naturwissenschaften.

The betaA4 amyloid peptide complexes to and enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway.

W. März, H. Scharnagl, T. Ohm, 1999, Laboratory investigation; a journal of technical methods and pathology.

Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia.

W. März, H. Wieland, K Winkler, 1999, Atherosclerosis.

Endothelial nitric oxide synthase gene GLU298->ASP variant — association with arterial hypertension, but not with coronary artery disease

W. März, B. Winkelmann, H. Wieland, 2000 .

Characterization of hemoglobin Würzburg (alpha2beta2 4(A1)Thr-->Asn), a new electrophoretically silent variant, by mass spectrometry and molecular modeling studies.

A. van Dorsselaer, M. Baumstark, H. Wieland, 2006, Journal of chromatography. A.

Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia.

W. März, H. Scharnagl, H. Wieland, 2001, Clinica chimica acta; international journal of clinical chemistry.

Rapid, Homogeneous Genotyping of Human Platelet Antigen 1 by Fluorescence Resonance Energy Transfer and Probe Melting Curves

W. März, M. Nauck, H. Wieland, 2001 .

MODULAR ANALYTICS: A New Approach to Automation in the Clinical Laboratory

Hiroshi Mitsumaki, Franz Keller, Gary L. Horowitz, 2005, Journal of automated methods & management in chemistry.

Hemoglobin Görwihl [alpha2beta(2)5(A2)Pro-->Ala], an electrophoretically silent variant with impaired glycation.

A. van Dorsselaer, L. Kiger, H. Wieland, 2003, Clinical chemistry.

Hemoglobin Görwihl [α2β25(A2)Pro→Ala], an Electrophoretically Silent Variant with Impaired Glycation

L. Kiger, H. Wieland, J. Kister, 2003 .

[A new and simplified method for the detection of LP-X, a cholestasis specific lipoprotein].

H. Wieland, D. Seidel, 1973, Deutsche Medizinische Wochenschrift.

Protection of rats against phalloidin by ligation of bile duct

H. Wieland, B. Agostini, A. Walli, 1978, Naturwissenschaften.

1.P.257 Mutations in the genes encoding the low-density lipoprotein receptor and apolipoprotein B in Southwest Germany

W. März, H. Scharnagl, H. Wieland, 1997 .

Improved Techniques for Assessment of Serum Lipoprotein Patterns. II. Rapid Method for Diagnosis of Type III Hyperlipoproteinemia without Ultracentrifugation

H. Wieland, 2004 .

Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine.

C. Wanner, W. Hörl, H. Wieland, 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Comparability of a new turbidimetric digoxin test with other immunochemical tests and with HPLC--a multicenter evaluation.

H. Wieland, M. Oellerich, D. Willems, 1997, Clinical chemistry.

Characterization of a New Electrophoretically Silent Hemoglobin Variant

A. van Dorsselaer, M. Marden, H. Wieland, 2000, The Journal of Biological Chemistry.

An investigation of the lipoprotein profiles of patients on hemofiltration as compared to those on hemodialysis and intermittent peritoneal dialysis.

V. Armstrong, H. Wieland, P. Cremer, 1982, Contributions to nephrology.

Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.

C. Wanner, H. Wieland, P. Schollmeyer, 1992, Nephron.